Intracameral Moxifloxacin: Should We Dilute It? How Much?
Published 2024 - 42nd Congress of the ESCRS
Reference: PO409 | Type: Free paper | DOI: 10.82333/wmq8-br82
Authors: Steve Aaron Arshinoff* 1
1Department of Ophthalmology and Vision Sciences,University of Toronto,Toronto,Canada;Ophthalmology,McMaster University,Hamilton,Canada
Purpose
To compare the advantages and disadvantages of possible administration dilutions of intracameral moxifloxacin.
Setting
York Finch Eey Associates and University of Toronto
Methods
Published studies on intracameral moxifloxacin toxicity, administration and bacterial resistance were reviewed to extract important issues and data, as available information is increasing.Factors affecting the ease of administration, efficacy and toxicity of different concentrations were assembled and compared.
Results
Diluting IC moxifloxacin to use 0.55 cc x 150 µg/0.1 mL is excellent for routine cases, but problematic when the dose must be increased in cases of posterior capsule rupture in order to attain the bactericidal concentration versus target pathogens of moxifloxacin resistant coagulase negative Staphylococci (CoNS) and methicillin resistant Staph aureus (MRSA). However, using 0.1 cc (500 µg) from the moxifloxacin bottle directly entails greater error potential in dose administration. We have compiled data on numerous possible dilutions and comparisons of administration dose accuracy and efficacy. More than one choice is reasonable.
Conclusions
The study of intracameral antibiotic administration methods and concentration decay can lead to selection of better prophylactic drugs, concentrations and methods, leading to reduction of the incidence of post-operative endophthalmitis.